Bristol Myers Squibb Presents New Data From 2-Trials Demonstrating Sotyktu Efficacy In both Moderate-To-Severe Scalp Psoriasis And In A Real-World Setting; In The Phase 3b/4 PSORIATYK SCALP Sotyktu Was Superior To Placebo Across All Primary And Secondary Endpoints At Week 16, With Patients Reporting Significantly Greater Improvement In Symptoms

In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16, with patients reporting significantly greater improvement in symptoms

Safety profile in PSORIATYK SCALP was consistent with the established safety profile of Sotyktu

In the real-world RePhlect registry of patients, six months of Sotyktu treatment was consistent with the efficacy outcomes observed in the POETYK clinical studies for psoriasis

Bristol Myers Squibb (NYSE:BMY) today announced positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu (deucravacitinib) for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in the scalp-specific Physician's Global Assessment (ss-PGA) response of 0 or 1 (clear/almost clear) at 16 weeks, with more than three times as many patients achieving ss-PGA 0/1 with Sotyktu treatment compared to those on placebo (48.5% versus 13.7%, respectively; p<0.0001).

The new PSORIATYK SCALP efficacy and safety results (oral presentation FC04.07, abstract #5627), patient-reported outcomes (oral presentation FC06.06, abstract #5390) and 23 additional abstracts are being presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands taking place September 25-28, 2024.